HomeMatch CenterScheduleMarketsLeaderboardMethodologyTrack RecordServicesPricingAboutContactFAQImpressumPrivacyTerms
Skip to content
Bucephus Logo
bucephus
Analytics with Intelligence
Loading match intelligence
Will the Phase 3 trial of 'GB-005' for moderate-to-severe acne meet its co-primary endpoints in a company press release by July 24, 2026? · Bucephus Markets